Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 156

1.

High-Sequence Diversity and Rapid Virus Turnover Contribute to Higher Rates of Coreceptor Switching in Treatment-Experienced Subjects with HIV-1 Viremia.

Nedellec R, Herbeck JT, Hunt PW, Deeks SG, Mullins JI, Anton ED, Reeves JD, Mosier DE.

AIDS Res Hum Retroviruses. 2017 Mar;33(3):234-245. doi: 10.1089/AID.2016.0153. Epub 2016 Oct 12.

2.

The Story Behind "A Requirement for Two Cell Types for Antibody Formation in vitro".

Mosier DE.

Front Immunol. 2014 Oct 17;5:495. doi: 10.3389/fimmu.2014.00495. eCollection 2014. Review. No abstract available.

3.

Adhesion and fusion efficiencies of human immunodeficiency virus type 1 (HIV-1) surface proteins.

Dobrowsky TM, Rabi SA, Nedellec R, Daniels BR, Mullins JI, Mosier DE, Siliciano RF, Wirtz D.

Sci Rep. 2013 Oct 22;3:3014. doi: 10.1038/srep03014.

4.

CCR5 mutations distinguish N-terminal modifications of RANTES (CCL5) with agonist versus antagonist activity.

Choi WT, Nedellec R, Coetzer M, Colin P, Lagane B, Offord RE, Hartley O, Mosier DE.

J Virol. 2012 Sep;86(18):10218-20. doi: 10.1128/JVI.00353-12. Epub 2012 Jul 11.

5.

Primary infection by a human immunodeficiency virus with atypical coreceptor tropism.

Jiang C, Parrish NF, Wilen CB, Li H, Chen Y, Pavlicek JW, Berg A, Lu X, Song H, Tilton JC, Pfaff JM, Henning EA, Decker JM, Moody MA, Drinker MS, Schutte R, Freel S, Tomaras GD, Nedellec R, Mosier DE, Haynes BF, Shaw GM, Hahn BH, Doms RW, Gao F.

J Virol. 2011 Oct;85(20):10669-81. doi: 10.1128/JVI.05249-11. Epub 2011 Aug 10.

6.

Resistance to the CCR5 inhibitor 5P12-RANTES requires a difficult evolution from CCR5 to CXCR4 coreceptor use.

Nedellec R, Coetzer M, Lederman MM, Offord RE, Hartley O, Mosier DE.

PLoS One. 2011;6(7):e22020. doi: 10.1371/journal.pone.0022020. Epub 2011 Jul 8.

7.

Circulating human CD4 and CD8 T cells do not have large intracellular pools of CCR5.

Pilch-Cooper HA, Sieg SF, Hope TJ, Koons A, Escola JM, Offord R, Veazey RS, Mosier DE, Clagett B, Medvik K, Jadlowsky JK, Chance MR, Kiselar JG, Hoxie JA, Collman RG, Riddick NE, Mercanti V, Hartley O, Lederman MM.

Blood. 2011 Jul 28;118(4):1015-9. doi: 10.1182/blood-2010-05-282509. Epub 2010 Nov 10.

8.

Extreme genetic divergence is required for coreceptor switching in HIV-1 subtype C.

Coetzer M, Nedellec R, Cilliers T, Meyers T, Morris L, Mosier DE.

J Acquir Immune Defic Syndr. 2011 Jan 1;56(1):9-15. doi: 10.1097/QAI.0b013e3181f63906.

9.

"Resistance" to PSC-RANTES revisited: two mutations in human immunodeficiency virus type 1 HIV-1 SF162 or simian-human immunodeficiency virus SHIV SF162-p3 do not confer resistance.

Nedellec R, Coetzer M, Lederman MM, Offord RE, Hartley O, Mosier DE.

J Virol. 2010 Jun;84(11):5842-5. doi: 10.1128/JVI.01907-09. Epub 2010 Mar 24.

10.

Fitness epistasis and constraints on adaptation in a human immunodeficiency virus type 1 protein region.

da Silva J, Coetzer M, Nedellec R, Pastore C, Mosier DE.

Genetics. 2010 May;185(1):293-303. doi: 10.1534/genetics.109.112458. Epub 2010 Feb 15.

11.

Virus entry via the alternative coreceptors CCR3 and FPRL1 differs by human immunodeficiency virus type 1 subtype.

Nedellec R, Coetzer M, Shimizu N, Hoshino H, Polonis VR, Morris L, Mårtensson UE, Binley J, Overbaugh J, Mosier DE.

J Virol. 2009 Sep;83(17):8353-63. doi: 10.1128/JVI.00780-09. Epub 2009 Jun 24.

12.

How HIV changes its tropism: evolution and adaptation?

Mosier DE.

Curr Opin HIV AIDS. 2009 Mar;4(2):125-30. doi: 10.1097/COH.0b013e3283223d61. Review.

13.

Evolution of CCR5 use before and during coreceptor switching.

Coetzer M, Nedellec R, Salkowitz J, McLaughlin S, Liu Y, Heath L, Mullins JI, Mosier DE.

J Virol. 2008 Dec;82(23):11758-66. doi: 10.1128/JVI.01141-08. Epub 2008 Sep 24.

14.

Whither or wither microbicides?

Grant RM, Hamer D, Hope T, Johnston R, Lange J, Lederman MM, Lieberman J, Miller CJ, Moore JP, Mosier DE, Richman DD, Schooley RT, Springer MS, Veazey RS, Wainberg MA.

Science. 2008 Jul 25;321(5888):532-4. doi: 10.1126/science.1160355.

15.

Changes in HIV-1 tropism: clinical and prognostic consequences.

Mosier DE.

Eur J Med Res. 2007 Oct 15;12(9):371-4. No abstract available.

PMID:
17933716
16.

Conserved changes in envelope function during human immunodeficiency virus type 1 coreceptor switching.

Pastore C, Nedellec R, Ramos A, Hartley O, Miamidian JL, Reeves JD, Mosier DE.

J Virol. 2007 Aug;81(15):8165-79. Epub 2007 May 16.

17.

HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry.

Blish CA, Nedellec R, Mandaliya K, Mosier DE, Overbaugh J.

AIDS. 2007 Mar 30;21(6):693-702.

PMID:
17413690
18.

Evolution of CXCR4-using human immunodeficiency virus type 1 SF162 is associated with two unique envelope mutations.

Kiselyeva Y, Nedellec R, Ramos A, Pastore C, Margolis LB, Mosier DE.

J Virol. 2007 Apr;81(7):3657-61. Epub 2007 Jan 3.

19.

High prevalence of infection with a single hepatitis C virus genotype in a small rural community of Argentina.

Picchio GR, Baré PC, Descalzi VI, Bussy MV, Soria SM, Raffa MP, Mazzencio NE, Etchehun S, Cámera JA, Mosier DE, Villamil FG.

Liver Int. 2006 Aug;26(6):660-5.

PMID:
16842321
20.
21.

HIV-1 envelope evolution and vaccine efficacy.

Mosier DE.

Curr Drug Targets Infect Disord. 2005 Jun;5(2):171-7. Review.

PMID:
15975022
22.

Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5.

Lederman MM, Veazey RS, Offord R, Mosier DE, Dufour J, Mefford M, Piatak M Jr, Lifson JD, Salkowitz JR, Rodriguez B, Blauvelt A, Hartley O.

Science. 2004 Oct 15;306(5695):485-7.

23.

Intrinsic obstacles to human immunodeficiency virus type 1 coreceptor switching.

Pastore C, Ramos A, Mosier DE.

J Virol. 2004 Jul;78(14):7565-74.

24.

Evolutionary genetics: CCR5 mutation and plague protection.

Mecsas J, Franklin G, Kuziel WA, Brubaker RR, Falkow S, Mosier DE.

Nature. 2004 Feb 12;427(6975):606.

PMID:
14961112
25.

CCR5 promoter polymorphism determines macrophage CCR5 density and magnitude of HIV-1 propagation in vitro.

Salkowitz JR, Bruse SE, Meyerson H, Valdez H, Mosier DE, Harding CV, Zimmerman PA, Lederman MM.

Clin Immunol. 2003 Sep;108(3):234-40.

26.

Two mechanisms for human immunodeficiency virus type 1 inhibition by N-terminal modifications of RANTES.

Pastore C, Picchio GR, Galimi F, Fish R, Hartley O, Offord RE, Mosier DE.

Antimicrob Agents Chemother. 2003 Feb;47(2):509-17.

28.

Immunogenicity of chi4127 phoP- Salmonella enterica serovar Typhimurium in dogs.

McVey DS, Chengappa MM, Mosier DE, Stone GG, Oberst RD, Sylte MJ, Gabbert NM, Kelly-Aehle SM, Curtiss R.

Vaccine. 2002 Feb 22;20(11-12):1618-23.

PMID:
11858870
29.

GB virus C and mortality from HIV infection.

Mosier DE, Chisari FV.

N Engl J Med. 2002 Jan 31;346(5):377-9. No abstract available.

30.

Donor- and ligand-dependent differences in C-C chemokine receptor 5 reexpression.

Sabbe R, Picchio GR, Pastore C, Chaloin O, Hartley O, Offord R, Mosier DE.

J Virol. 2001 Jan;75(2):661-71.

31.

Altered viral fitness of HIV-1 following failure of protease inhibitor-based therapy.

Picchio GR, Valdez H, Sabbe R, Landay AL, Kuritzkes DR, Lederman MM, Mosier DE.

J Acquir Immune Defic Syndr. 2000 Dec 1;25(4):289-95.

PMID:
11114828
32.

Human xenograft models for virus infection.

Mosier DE.

Virology. 2000 Jun 5;271(2):215-9. Review. No abstract available.

33.

Virus and target cell evolution in human immunodeficiency virus type 1 infection.

Mosier DE.

Immunol Res. 2000;21(2-3):253-8. Review.

PMID:
10852125
34.

Type I consensus IFN (IFN-con1) gene transfer into KSHV/HHV-8-infected BCBL-1 cells causes inhibition of viral lytic cycle activation via induction of apoptosis and abrogates tumorigenicity in sCID mice.

D'Agostino G, Aricò E, Santodonato L, Venditti M, Sestili P, Masuelli L, Coletti A, Modesti A, Picchio G, Mosier DE, Ferrantini M, Belardelli F.

J Interferon Cytokine Res. 1999 Nov;19(11):1305-16.

PMID:
10574624
35.

The antiviral activity of HIV-specific CD8+ CTL clones is limited by elimination due to encounter with HIV-infected targets.

McKinney DM, Lewinsohn DA, Riddell SR, Greenberg PD, Mosier DE.

J Immunol. 1999 Jul 15;163(2):861-7.

36.

Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo.

Poignard P, Sabbe R, Picchio GR, Wang M, Gulizia RJ, Katinger H, Parren PW, Mosier DE, Burton DR.

Immunity. 1999 Apr;10(4):431-8.

37.

Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants.

Mosier DE, Picchio GR, Gulizia RJ, Sabbe R, Poignard P, Picard L, Offord RE, Thompson DA, Wilken J.

J Virol. 1999 May;73(5):3544-50.

38.

Transduction of human CD34+ cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors.

Miyoshi H, Smith KA, Mosier DE, Verma IM, Torbett BE.

Science. 1999 Jan 29;283(5402):682-6.

39.

Epstein-Barr virus and lymphoproliferative disease.

Mosier DE.

Curr Opin Hematol. 1999 Jan;6(1):25-9. Review.

PMID:
9915550
40.

Inhibition of RNA polymerase II transcription in human cells by synthetic DNA-binding ligands.

Dickinson LA, Gulizia RJ, Trauger JW, Baird EE, Mosier DE, Gottesfeld JM, Dervan PB.

Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):12890-5.

41.

Early modification of host cell gene expression induced by HIV-1.

Scheuring UJ, Corbeil J, Mosier DE, Theofilopoulos AN.

AIDS. 1998 Apr 16;12(6):563-70.

PMID:
9583595
42.

The cell tropism of human immunodeficiency virus type 1 determines the kinetics of plasma viremia in SCID mice reconstituted with human peripheral blood leukocytes.

Picchio GR, Gulizia RJ, Wehrly K, Chesebro B, Mosier DE.

J Virol. 1998 Mar;72(3):2002-9. Erratum in: J Virol 1998 Sep;72(9):7707.

43.
44.

CD4+ T cells from IRF-1-deficient mice exhibit altered patterns of cytokine expression and cell subset homeostasis.

McElligott DL, Phillips JA, Stillman CA, Koch RJ, Mosier DE, Hobbs MV.

J Immunol. 1997 Nov 1;159(9):4180-6.

PMID:
9379011
46.
47.

Common and idiosyncratic patterns of cytokine gene expression by Epstein-Barr virus transformed human B cell lines.

Rochford R, Cannon MJ, Sabbe RE, Adusumilli K, Picchio G, Glynn JM, Noonan DJ, Mosier DE, Hobbs MV.

Viral Immunol. 1997;10(4):183-95.

PMID:
9473149
48.
49.

Modeling AIDS in a mouse.

Mosier DE.

Hosp Pract (1995). 1996 Sep 15;31(9):41-8, 53-5, 59-60. Review.

PMID:
8814120
50.

Viral pathogenesis in hu-PBL-SCID mice.

Mosier DE.

Semin Immunol. 1996 Aug;8(4):255-62. Review. Erratum in: Semin Immunol 1996 Oct;8(5):311.

PMID:
8883149

Supplemental Content

Loading ...
Support Center